Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
Open label RCT (n=275) found no significant differences in event free survival and overall survival after 10 years of follow up for eight cycles of conventional chemotherapy plus rituximab (R-CHOEP-14) vs four cycles of high-dose chemotherapy plus rituximab (R-MegaCHOEP).
Source:
The Lancet Haematology